What is the core issue with Huntington's disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

The Core Issue with Huntington's Disease

The fundamental problem in Huntington's disease is an expanded CAG trinucleotide repeat (≥40 repeats) in the HTT gene that produces a mutant huntingtin protein with an abnormally long polyglutamine stretch, causing direct neurotoxicity and progressive neuronal death, particularly in the caudate nucleus and putamen. 1

Genetic Mechanism

  • The disease is caused by expansion of a polymorphic CAG repeat in exon 1 of the HTT gene on chromosome 4, with full penetrance occurring at ≥40 repeats and variable penetrance at 36-39 repeats 1

  • This CAG expansion is inherited in an autosomal dominant manner, meaning a single copy of the mutated gene from either parent will cause disease 1

  • The expanded CAG repeat translates into an abnormally long polyglutamine (polyQ) stretch at the N-terminus of the huntingtin protein, which is the molecular basis for protein toxicity 2, 3

Pathophysiological Consequences

  • The mutant huntingtin protein (mHTT) causes direct neurotoxicity through abnormal protein processing and aggregation, leading to selective neuronal vulnerability and death 4, 3

  • Neuronal loss occurs most notably in the caudate nucleus and putamen (the striatum), though the mutant protein is expressed throughout the brain and body during the entire lifetime 1

  • This is NOT an autoimmune or immune-mediated disease—the pathology results from direct cellular toxicity from the mutant protein, not immune system involvement 4

Clinical Impact on Morbidity and Mortality

  • The disease produces a devastating triad of progressive motor dysfunction (choreic movements, rigidity), cognitive decline, and psychiatric disturbances over a 15-20 year course 1, 5, 2

  • There is currently no effective disease-modifying treatment—all available therapies are purely symptomatic 1, 4

  • The disease is uniformly fatal, with relentless progression once manifest symptoms appear 5, 2

Critical Pitfall to Understand

  • The disease begins many years before diagnosable symptoms appear—neurodegeneration and subtle prodromal changes in cognition, motor function, and behavior occur long before clinical diagnosis 3

  • Genetic testing with CAG repeat quantification provides 100% specificity for diagnosis when ≥40 repeats are present, making this a definitive molecular diagnosis rather than a clinical one 1, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clinical Features of Huntington's Disease.

Advances in experimental medicine and biology, 2018

Guideline

Huntington Disease Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clinical Aspects of Huntington's Disease.

Current topics in behavioral neurosciences, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.